Next Article in Journal
Mitogenome Characteristics and Intracellular Gene Transfer Analysis of Four Adansonia Species
Previous Article in Journal
Global Transcriptome and Weighted Gene Co-Expression Network Analyses of Cold Stress Responses in Chinese Cabbage
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 16
Issue 7
10.3390/genes16070844
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Placental Expression of Sirtuins in Women with Gestational Diabetes

by
Michał Czerewaty
1,
Łukasz Ustianowski
1,
Kajetan Kiełbowski
1,
Estera Bakinowska
1,
Krzysztof Safranow
2,
Maciej Tarnowski
3,
Tomasz Sroczyński
1 and
Andrzej Pawlik
1,*
1
Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland
2
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
3
Department of Physiology in Health Sciences, Pomeranian Medical University, 70-210 Szczecin, Poland
*
Author to whom correspondence should be addressed.
Genes 2025, 16(7), 844; https://doi.org/10.3390/genes16070844
Submission received: 23 June 2025 / Revised: 16 July 2025 / Accepted: 18 July 2025 / Published: 20 July 2025
(This article belongs to the Section Molecular Genetics and Genomics)
Browse Figures
Versions Notes

Abstract

Background/Objectives: Gestational diabetes mellitus (GDM) is a common metabolic disorder in pregnant women. It can lead to several complications, such as preterm delivery, macrosomia, or metabolic disorders in newborns. Studies have revealed morphological and transcriptional differences between the placentas of patients with GDM and women with normal glucose tolerance. Sirtuins (SIRTs) are nicotinamide adenine dinucleotide-dependent deacetylases that interact with and regulate the activity of numerous proteins. However, little is known about their role in the pathogenesis of GDM. This study was performed to analyze the placental expression of SIRTs and investigate their correlations with clinical parameters. Methods: GDM was diagnosed based on the 75 g oral glucose tolerance test in accordance with the criteria developed by the International Association of Diabetes and Pregnancy Study Groups. Placental tissues were collected, and the expression of SIRT1,-3,-4 and a reference gene (β-2 microglobulin) was analyzed. Results: The placental expression of SIRT1 and SIRT3 was elevated in women with GDM. However, there was no significant difference in SIRT4 expression between women with GDM and those with normal glucose tolerance. Furthermore, we found no significant correlations between SIRT1, SIRT3, and SIRT4 expression and clinical parameters. Conclusions: The findings of this study demonstrate elevated expression of SIRT1 and SIRT3 in the placentas of women with GDM. Further studies are required to confirm our observations and demonstrate the precise role of these enzymes in GDM.

1. Introduction

Many changes occur during pregnancy that make it easier to provide the nutrients and oxygen needed for the growing fetus. Because the fetus is dependent on maternal glucose delivery, these adaptations also involve glucose metabolism. For instance, the placenta secretes hormones such as human chorionic gonadotropin (hCG), human placental lactogen (hPL), and human placental growth hormone (hPGH) that may induce a state of insulin resistance [1]. Furthermore, changes in the efficacy of gluconeogenesis occur throughout pregnancy [1]. A state of hyperglycemia that is first recognized during pregnancy is known as gestational diabetes mellitus (GDM). According to the Diabetes Atlas of the International Diabetes Federation, the global prevalence of GDM in 2021 was 14% [2]. This metabolic disorder has been associated with several complications, including macrosomia, preterm delivery, and increased caesarean section rates, among others [3]. The pathogenesis of GDM is unclear; therefore, understanding the pathophysiological processes associated with GDM could result in the development of better treatment strategies.
Sirtuins (SIRTs) are nicotinamide adenine dinucleotide-dependent deacetylases that catalyze post-translational modifications of proteins. Seven members of the SIRT family (Sirtuin-1,-2,-3,-4,-5,-6,-7) have been identified in mammals, and the modifications that they perform involve deacetylation, ADP-ribosylation, and decrotonylation, among others [4]. SIRTs interact with numerous proteins, thus modulating their activity [5].
Consequently, their dysregulation has been suggested to play a role in the pathogenesis of various diseases. For instance, reduced placental expression of the SIRT1 gene has been found in patients with preeclampsia [6]. However, the data regarding their role in the placentas of patients with GDM are limited. In this study, we examined the placental expression of SIRT1, SIRT3, and SIRT4 in women with GDM and their correlations with clinical parameters.

2. Materials and Methods

2.1. Participants

This case–control study involved 26 women with GDM and 28 pregnant women with normal glucose tolerance. The clinical characteristics of women with GDM and women in the control group are shown in Table 1. The diagnosis of GDM was established in accordance with the criteria of the International Association of Diabetes and Pregnancy Study Groups [7]. A 75 g oral glucose tolerance test was performed, and GDM was diagnosed if the fasting glucose level was ≥92 mg/dL with 1- and 2 h plasma glucose concentrations of >180 and >153 mg/dL, respectively. The following clinical parameters were analyzed: age; fasting glucose concentration; daily insulin requirement; body mass index; body mass before pregnancy, at birth, and throughout pregnancy; newborn mass; and Apgar score. In the GDM cohort, 78% of patients were treated with diet alone and 22% were treated with diet and insulin until delivery. Insulin therapy was initiated if morning glycemia exceeded 95 mg/dL for 3 consecutive days despite an adequate diet or if the blood glucose level exceeded 140 mg/dL after a meal. The initial dose of insulin was 0.7 IU/kg body weight once daily, and it was adjusted according to the blood glucose concentration.
The study excluded women with acute or chronic complications such as diabetic ketoacidosis, as well as other disorders of glucose metabolism, autoimmune diseases, and chronic non-inflammatory diseases. Written consent for participation was obtained from all women, and the study was approved by the Ethics Committee of Pomeranian Medical University, Szczecin, Poland (KB-0012/40/14).

2.2. RNA Isolation

Placentas were collected from women who had undergone a natural delivery after 37 weeks of gestation at the Department of Obstetrics and Gynecology of Pomeranian Medical University. The tissues were transported to the Department of Physiology in a container with 0.9% NaCl solution. Approximately 100 mg of tissue was resected from the maternal side of the cotyledons for RNA extraction. No blood vessels, calcium deposits, or connective tissues were present in the study samples. Tissue samples were cut into small fragments and immediately stored in RNAlater® Solution (Thermo Fisher Scientific, Waltham, MA, USA) at −80 °C until the time of genetic analysis. An RNeasy Mini Kit (Qiagen, Hilden, Germany) was used for RNA extraction in accordance with the manufacturer’s protocol. A DeNovix DS-11 FX spectrophotometer (DeNovix, Wilmington, DE, USA) was used to determine the RNA concentration and purity.

2.3. Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction

In total, 0.4 μg of RNA from each sample was reverse-transcribed into copy DNA (cDNA) in a total volume of 20 μL using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The quantitative expression of SIRT1, SIRT3, SIRT4, and a reference gene was analyzed using real-time quantitative reverse-transcription polymerase chain reaction on an ABI PRISM® Fast 7500 Sequence Detection System (Applied Biosystems, Waltham, MA, USA), as previously described. The reference gene [β-2 microglobulin (B2M)] was determined based on the available literature [8,9,10]. A total of 2 μL of cDNA was present in each reaction. Two technical repeats were performed for each sample analysis, and the mean cycle threshold (Ct) values were used in further calculations. The final values were calculated with the comparative Ct method (2−ΔCt method). The following primers were used for gene expression analysis:
  • B2M forward: 5′-AATGCGGCATCTTCAAACCT-3′
  • B2M reverse: 5′-TGACTTTGTCACAGCCCAAGA-3′
  • SIRT1 forward: 5′-ACGCTGGAACAGGTTGCGGG-3′
  • SIRT1 reverse: 5′-AGCGGTTCATCAGCTGGGCAC-3′
  • SIRT3 forward: 5′-AAGTGTTGTTGGAAGTGGAG-3′
  • SIRT3 reverse: 5′-TGTGAAAGAAGAATGGGAGT-3′
  • SIRT4 forward: 5′-AGACTCCTTGTGATGACTGG-3′
  • SIRT4 reverse: 5′-AGTACAGCTTTCCGAGTTTC-3′

2.4. Statistical Analysis

Statistical analysis was performed using STATISTICA version 13 (TIBCO Software, Inc., Palo Alto, CA, USA). Since the distributions of quantitative variables differed significantly from the normal distribution (Shapiro–Wilk test), non-parametric tests were used. Expression of SIRTs in the placenta was compared using the Mann–Whitney test. Spearman’s rank correlation coefficient (Rs) was used to examine the relationships between placental gene expression and clinical parameters.
Our study including 28 GDM women and 26 non-GDM controls had sufficient statistical power to detect with 80% probability true associations, corresponding to 0.78 of standard deviation of gene expression for difference between the groups and |Rs| > 0.5 for correlations within the GDM group. p-values of <0.05 were considered statistically significant. Results are presented as scatterplots where each dot represents one individual from the data set.

3. Results

The placental expression of SIRT1 (p = 0.01963) and SIRT3 (p = 0.00008) was significantly higher in women with GDM than in women with normal glucose tolerance (Figure 1 and Figure 2). In contrast, there was no difference in the expression of SIRT4 (Figure 3).
We also examined the correlations between placental expression of SIRT1, SIRT3, and SIRT4 and selected clinical parameters in pregnant women with GDM. However, no significant correlations were found (Table 2, Table 3 and Table 4).

4. Discussion

GDM is a common metabolic disorder, and its pathophysiology remains unclear. Recent studies have demonstrated functional alterations and transcriptional differences in the placentas between patients with GDM and healthy controls [11]. Specifically, the placentas of patients with GDM show significantly greater villous immaturity than those of patients with type 1 and 2 diabetes [12]. In a recent study by Aldahmash et al. [13], placentas from patients with GDM showed several vasculopathies, including villous agglutination, retroplacental hemorrhage, calcification, and villous fibroid necrosis, among others. Furthermore, multiple differentially expressed genes between GDM and control placentas have been identified. Significantly upregulated genes (such as SLC1A6, ADRB1, and SLC1A2) may be involved in processes associated with antigen presentation and estrogen signaling [11].
Sirtuins are regulators of many cellular processes and metabolic pathways that occur in various tissues, such as skeletal muscle, pancreas, and liver. All of these tissues are involved in carbohydrate metabolism, tissue glucose transport, and the occurrence of insulin resistance [14]. Mitochondrial sirtuins are important regulators of cellular energy processes. Disruption of these processes can be one of the causes of impaired insulin production in the pancreas or the occurrence of insulin resistance in muscle tissue [4]. Also in pregnant women, sirtuins have important regulatory functions through which they regulate carbohydrate metabolism and may influence the development of GDM [15]. Sirtuins appear to be regulators that, at multiple levels and in various tissues, are responsible for controlling many metabolic processes, including those that may lead to the development of GDM. Previous studies indicate that sirtuins play an important role in the development of GDM, not only in the placenta of pregnant women, but also in tissues such as the pancreas, liver, and skeletal muscle [16]. Sirtuins can affect both insulin secretion and the development of insulin resistance.
Sirtuins regulate multiple signaling pathways that influence the development of inflammation, one of the causes of GDM [17,18]. Sirtuins regulate the NF-κB pathway, which plays an important role in inflammatory processes. They also influence TLR receptors, particularly TLR4, which play an important role in inflammatory responses in tissues, taking part in the secretion of pro-inflammatory cytokines and other mediators [19,20].
In this study, we found increased expression of placental SIRT1 and SIRT3 in women with GDM. These enzymes take part in major cellular mechanisms, and dysregulation of their expression has been associated with metabolic disorders. For instance, downregulation of SIRT1 was found in peripheral blood mononuclear cells of patients with metabolic syndrome and insulin resistance [21]. Conversely, overexpression of SIRT1 improves insulin sensitivity [22]. In addition, altered expression of SIRTs has been found in placental tissue of women with pregnancy complications, such as preeclampsia [6] and fetal growth restriction [23].
Members of the SIRT family are expressed in the placenta [24], and they have been suggested to take part in its physiological development. Deficiency of SIRT1 and SIRT3 is associated with various dysfunctions of trophoblasts [25,26]. In addition, overexpression of SIRT2 in trophoblasts improves their viability [27]. Nevertheless, the expression and role of SIRTs in the pathogenesis of GDM remain unclear. To date, there are only few papers that present often contradictory results regarding the role of sirtuins in the pathogenesis of GDM. Upregulation of SIRT1 mRNA expression has been observed in leukocytes of patients with GDM [28]. In line with our findings, Zhang et al. [29] recently found elevated mRNA and protein expression of SIRT1 in placental tissue of patients with GDM. Intriguingly, elevated protein expression of PI3K/AKT was also observed. In subsequent analyses, the authors demonstrated that the placenta produced exosomes containing microRNA-135a-5p, which promotes SIRT1 and PI3K/AKT expression, suggesting that SIRT1 controls the pathogenesis of GDM [30]. The opposite results were observed by Han et al., who detected significantly lower levels of SIRT1 expression in the placental tissue and serum of their GDM group compared to controls [31].
SIRT1 regulates important processes of autophagy, senescence, and the response to oxidative stress in the placenta [32]. Autophagy is involved in the preservation of energy homeostasis, and studies have shown that this process is impaired in the placentas of patients with GDM [33,34]. SIRTs are deacetylases, and their altered expression may therefore result in abnormal profiles of acetylated proteins. Indeed, a recent study by Hu et al. [34] revealed numerous differently regulated acetylated proteins in placental tissues of patients with GDM. Furthermore, another study demonstrated that endothelial cells derived from umbilical cord tissue of patients with GDM had impaired antioxidant activity and showed senescent markers [35]. Interestingly, the authors found that the endothelial cells exerted reduced SIRT1 activity but elevated SIRT1 protein and mRNA expression. These results were accompanied by increased expression of acetyltransferase p300 and acetylated p53 [36]. Thus, the elevated expression of SIRT1 and SIRT3 observed in the present study could also represent the compensatory mechanisms. SIRT1 transcription is regulated by various transcription factors, including P53, as well as by negative feedback loops, causing SIRT1 expression to change depending on the metabolic state of cells [37,38,39,40,41].
Sirtuin 3 (SIRT3) is mainly found in mitochondria and is responsible for regulating metabolic processes, protecting cells from mitochondrial dysfunction and oxidative stress [42]. SIRT3 deficiency exacerbated hyperglycemia-induced mitochondrial damage and increased ROS accumulation [43,44]. SIRT3 is regulated by various mechanisms at the transcriptional and post-translational levels [45,46]. SIRT3 is a regulator of mitochondrial metabolism, and thus NAD+ and nicotinamide levels are direct regulators of its activity [47,48]. An important factor regulating the expression of both SIRT1 and SIRT3 is diet-related calorie availability [49,50,51,52,53,54]. The observed inter-population differences in sirtuin expression in the placenta of GDM women may be due to ethnic differences, the influence of diet and thus caloric availability, as well as factors affecting the transcriptional and post-transcriptional mechanisms regulating sirtuin expression [54,55,56].
Sirtuin 4 is a mitochondrial sirtuin that regulates the processes of lipid and carbohydrate metabolism [57]. The role of SIRT4 has not yet been extensively studied in the pathogenesis of GDM, but it has been shown that SIRT4 can also affect insulin secretion in pancreatic beta cells [58]. SIRT4 regulates adenine nucleotide translocase 2 (ANT2) activity and leucine catabolism, and thereby affects cellular ATP concentrations and pancreatic insulin secretion. Decreased expression of SIRT4 has been shown to activate NF-κB, resulting in increased inflammation. This also results in increased expression of cyclooxygenase-2 (COX2) and adhesion molecules, as well as increased synthesis of pro-inflammatory cytokines [59]. SIRT4 also inhibits the synthesis of apoptosis-increasing proteins such as p38 protein, Bax, and NADPH oxidases [59,60]. It was shown that fetal endothelial colony-forming cells (ECFCs) and human umbilical vein endothelial cells (HUVECs) from women with GDM had lower SIRT4 expression, which may result in the long-term cardiovascular complications observed in the offspring of pregnancies with GDM [61]. It has also been shown that in the early stages of diabetes mellitus type 2, SIRT4 levels may be reduced, which can result in the development of insulin resistance [14,62]. On the other hand, in advanced type 2 diabetes with its complications, an increase of SIRT4 in peripheral blood mononuclear cells was observed, which was explained by a feedback mechanism increasing SIRT4 levels [63].
Our study has several limitations. The main limitation of the study is the lack of determination of sirtuin proteins in placentas, as mRNA levels do not always correlate with protein expression, especially considering post-translational regulation. The study is also limited by the lack of histological evaluation of placental tissue.
The increased expression of SIRT1 and SIRT3 in the placenta shown in our study may suggest the involvement of these sirtuins in the pathogenesis of GDM. The pathogenesis of GDM is complex and involves a number of genetic, metabolic and environmental factors [46]. GDM is characterized by low-grade inflammation and infiltration of the placenta by immune cells, as well as metabolic changes in the placenta [47]. It is likely that some of the pro-inflammatory mediators or metabolites present in women with GDM may increase the expression of SIRT1 and SIRT3 in the placenta. However, understanding these mechanisms requires further research.

5. Conclusions

The present study revealed elevated expression of SIRT1 and SIRT3 in the placentas of patients with GDM. However, this elevated expression was not correlated with clinical parameters. Further research is required to confirm our observations and elucidate the role of SIRTs in the pathogenesis of GDM.

Author Contributions

Conceptualization, A.P.; methodology, M.C.; software, K.S.; formal analysis, M.T. and T.S.; investigation, M.C. and Ł.U.; writing—original draft preparation, A.P., K.K. and E.B.; writing—review and editing, A.P. and K.K.; supervision, A.P.; project administration, A.P.; funding acquisition, A.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects/patients were approved by the Ethical Committee of the Pomeranian University in Szczecin (Poland), number KB-0012/69/17, Approval Date 15 May 2017.

Informed Consent Statement

Written informed consent was obtained from all patients.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Parrettini, S.; Caroli, A.; Torlone, E. Nutrition and Metabolic Adaptations in Physiological and Complicated Pregnancy: Focus on Obesity and Gestational Diabetes. Front. Endocrinol. 2020, 11, 611929. [Google Scholar] [CrossRef] [PubMed]
  2. Wang, H.; Li, N.; Chivese, T.; Werfalli, M.; Sun, H.; Yuen, L.; Hoegfeldt, C.A.; Elise Powe, C.; Immanuel, J.; Karuranga, S.; et al. IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s Criteria. Diabetes Res. Clin. Pract. 2022, 183, 109050. [Google Scholar] [CrossRef] [PubMed]
  3. Ye, W.; Luo, C.; Huang, J.; Li, C.; Liu, Z.; Liu, F. Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes: Systematic Review and Meta-Analysis. BMJ 2022, 377, e067946. [Google Scholar] [CrossRef] [PubMed]
  4. Houtkooper, R.H.; Pirinen, E.; Auwerx, J. Sirtuins as Regulators of Metabolism and Healthspan. Nat. Rev. Mol. Cell Biol. 2012, 13, 225–238. [Google Scholar] [CrossRef] [PubMed]
  5. Wątroba, M.; Szukiewicz, D. The Role of Sirtuins in Aging and Age-Related Diseases. Adv. Med. Sci. 2016, 61, 52–62. [Google Scholar] [CrossRef] [PubMed]
  6. Yu, H.; Chen, L.; Du, P.; Liu, X.; Xia, Y. Effects of Sirtuin 1 Deficiency on Trophoblasts and Its Implications in the Pathogenesis of Pre-Eclampsia. J. Obstet. Gynaecol. 2023, 43, 2282103. [Google Scholar] [CrossRef] [PubMed]
  7. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care 2010, 33, 676–682. [Google Scholar] [CrossRef] [PubMed]
  8. Fajardy, I.; Moitrot, E.; Vambergue, A.; Vandersippe-Millot, M.; Deruelle, P.; Rousseaux, J. Time Course Analysis of RNA Stability in Human Placenta. BMC Mol. Biol. 2009, 10, 21. [Google Scholar] [CrossRef] [PubMed]
  9. Meller, M.; Vadachkoria, S.; Luthy, D.A.; Williams, M.A. Evaluation of Housekeeping Genes in Placental Comparative Expression Studies. Placenta 2005, 26, 601–607. [Google Scholar] [CrossRef] [PubMed]
  10. Karahoda, R.; Robles, M.; Marushka, J.; Stranik, J.; Abad, C.; Horackova, H.; Tebbens, J.D.; Vaillancourt, C.; Kacerovsky, M.; Staud, F. Prenatal Inflammation as a Link between Placental Expression Signature of Tryptophan Metabolism and Preterm Birth. Hum. Mol. Genet. 2021, 30, 2053–2067. [Google Scholar] [CrossRef] [PubMed]
  11. Yang, Y.; Guo, F.; Peng, Y.; Chen, R.; Zhou, W.; Wang, H.; OuYang, J.; Yu, B.; Xu, Z. Transcriptomic Profiling of Human Placenta in Gestational Diabetes Mellitus at the Single-Cell Level. Front. Endocrinol. 2021, 12, 679582. [Google Scholar] [CrossRef] [PubMed]
  12. Huynh, J.; Yamada, J.; Beauharnais, C.; Wenger, J.B.; Thadhani, R.I.; Wexler, D.; Roberts, D.J.; Bentley-Lewis, R. Type 1, Type 2 and Gestational Diabetes Mellitus Differentially Impact Placental Pathologic Characteristics of Uteroplacental Malperfusion. Placenta 2015, 36, 1161–1166. [Google Scholar] [CrossRef] [PubMed]
  13. Aldahmash, W.M.; Alwasel, S.H.; Aljerian, K. Gestational Diabetes Mellitus Induces Placental Vasculopathies. Environ. Sci. Pollut. Res. 2022, 29, 19860–19868. [Google Scholar] [CrossRef] [PubMed]
  14. Zgutka, K.; Tkacz, M.; Grabowska, M.; Mikołajek-Bedner, W.; Tarnowski, M. Sirtuins and Their Implications in the Physiopathology of Gestational Diabetes Mellitus. Pharmaceuticals 2025, 18, 41. [Google Scholar] [CrossRef] [PubMed]
  15. Kahmini, F.R.; Ghaleh, H.D.; Shahgaldi, S. Sirtuins: Subtle Regulators Involved in Convoluted Mechanisms of Pregnancy. Cell Physiol. Biochem. 2022, 56, 644–662. [Google Scholar] [PubMed]
  16. Joaquim, V.H.A.; da Silva, J.G.; Jannig, P.R. Understanding the role of sirtuin 1 in muscle physiology during androgen deprivation. J. Physiol. 2023, 601, 4659–4660. [Google Scholar] [CrossRef] [PubMed]
  17. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444, 840–846. [Google Scholar] [CrossRef] [PubMed]
  18. Moyce, B.L.; Dolinsky, V.W. Maternal beta-Cell Adaptations in Pregnancy and Placental Signalling: Implications for Gestational Diabetes. Int. J. Mol. Sci. 2018, 19, 3467. [Google Scholar] [CrossRef] [PubMed]
  19. Tsiotra, P.C.; Halvatsiotis, P.; Patsouras, K. Circulating adipokines and mRNA expression in adipose tissue and the placenta in womenwith gestational diabetes mellitus. Peptides 2018, 101, 157–166. [Google Scholar] [CrossRef] [PubMed]
  20. Han, C.S.; Herrin, M.A.; Pitruzzello, M.C.; Mulla, M.J.; Werner, E.F.; Pettker, C.M.; Flannery, C.A.; Abrahams, V.M. Glucose and metformin modulate human first trimester trophoblast function: A model and potential therapy for diabetes-associated uteroplacental insufficiency. Am. J. Reprod. Immunol. 2015, 73, 362–371. [Google Scholar] [CrossRef] [PubMed]
  21. Ge, Y.; Liu, X.; Huang, H. Advances in the role of silence information regulator family in pathological pregnancy. Zhejiang Da Xue Xue Bao Yi Xue Ban 2021, 50, 335–344. [Google Scholar] [CrossRef] [PubMed]
  22. De Kreutzenberg, S.V.; Ceolotto, G.; Papparella, I.; Bortoluzzi, A.; Semplicini, A.; Man, C.D.; Cobelli, C.; Fadini, G.P.; Avogaro, A. Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms. Diabetes 2010, 59, 1006–1015. [Google Scholar] [CrossRef] [PubMed]
  23. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q. SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B. Cell Metab. 2007, 6, 307–319. [Google Scholar] [CrossRef] [PubMed]
  24. Kojima, J.; Dai, Y.; Suzuki, T.; Ono, M.; Nishi, H. Sirtuin 1 Is a Potential Therapeutic Candidate Gene for Fetal Growth Restriction via Insulin-like 4. J. Matern.-Fetal Neonatal Med. 2023, 36, 2253486. [Google Scholar] [CrossRef] [PubMed]
  25. Xiong, L.; Ye, X.; Chen, Z.; Fu, H.; Li, S.; Xu, P.; Yu, J.; Wen, L.; Gao, R.; Fu, Y.; et al. Advanced Maternal Age-associated SIRT1 Deficiency Compromises Trophoblast Epithelial−Mesenchymal Transition through an Increase in Vimentin Acetylation. Aging Cell 2021, 20, e13491. [Google Scholar] [CrossRef] [PubMed]
  26. Yu, H.; Zhang, Y.; Liu, M.; Liao, L.; Wei, X.; Zhou, R. SIRT3 Deficiency Affects the Migration, Invasion, Tube Formation and Necroptosis of Trophoblast and Is Implicated in the Pathogenesis of Preeclampsia. Placenta 2022, 120, 1–9. [Google Scholar] [CrossRef] [PubMed]
  27. Yu, Y.; An, X.; Fan, D. Histone Deacetylase Sirtuin 2 Enhances Viability of Trophoblasts Through P65-Mediated MicroRNA-146a/ACKR2 Axis. Reprod. Sci. 2021, 28, 1370–1381. [Google Scholar] [CrossRef] [PubMed]
  28. Turek, I.; Wozniak, L.; Cypryk, K.; Nadel, I.; Wojcik, M. Evaluation of Leukocyte SIRT1 Expression in Women with Gestational Diabetes Mellitus (GDM) in the Third Trimester of Pregnancy. Diabetol. Klin. 2014, 3, 3–11. [Google Scholar]
  29. Zhang, Q.; Ye, X.; Xu, X.; Yan, J. Placenta-derived Exosomal miR-135a-5p Promotes Gestational Diabetes Mellitus Pathogenesis by Activating PI3K/AKT Signalling Pathway via SIRT1. J. Cell. Mol. Med. 2023, 27, 3729–3743. [Google Scholar] [CrossRef] [PubMed]
  30. Han, N.; Chang, X.; Yuan, Z.; Wang, Y. Expression and Correlation Analysis of Silent Information Regulator 1 (SIRT1), Sterol Regulatory Element-Binding Protein-1 (SREBP1), and Pyroptosis Factor in Gestational Diabetes Mellitus. J. Matern.-Fetal Neonatal Med. 2024, 37, 2311809. [Google Scholar] [CrossRef] [PubMed]
  31. Wątroba, M.; Szewczyk, G.; Szukiewicz, D. The Role of Sirtuin-1 (SIRT1) in the Physiology and Pathophysiology of the Human Placenta. IJMS 2023, 24, 16210. [Google Scholar] [CrossRef] [PubMed]
  32. Avagliano, L.; Massa, V.; Terraneo, L.; Samaja, M.; Doi, P.; Bulfamante, G.P.; Marconi, A.M. Gestational Diabetes Affects Fetal Autophagy. Placenta 2017, 55, 90–93. [Google Scholar] [CrossRef] [PubMed]
  33. Li, Y.; Long, D.; Liu, J.; Qiu, D.; Wang, J.; Cheng, X.; Yang, X.; Li, R.; Wang, G. Gestational Diabetes Mellitus in Women Increased the Risk of Neonatal Infection via Inflammation and Autophagy in the Placenta. Medicine 2020, 99, e22152. [Google Scholar] [CrossRef] [PubMed]
  34. Hu, B.; Li, D.; Tang, D.; Shangguan, Y.; Cao, Y.; Guo, R.; Luan, S.; Yun, C.; Morgera, S.; Hocher, B.; et al. Integrated Proteome and Acetylome Analyses Unveil Protein Features of Gestational Diabetes Mellitus and Preeclampsia. Proteomics 2022, 22, 2200124. [Google Scholar] [CrossRef] [PubMed]
  35. Di Tomo, P.; Alessio, N.; Falone, S.; Pietrangelo, L.; Lanuti, P.; Cordone, V.; Santini, S.J.; Di Pietrantonio, N.; Marchisio, M.; Protasi, F.; et al. Endothelial Cells from Umbilical Cord of Women Affected by Gestational Diabetes: A Suitable in Vitro Model to Study Mechanisms of Early Vascular Senescence in Diabetes. FASEB J. 2021, 35, e21662. [Google Scholar] [CrossRef] [PubMed]
  36. Yang, Y.; Liu, Y.; Wang, Y.; Chao, Y.; Zhang, J.; Jia, Y.; Tie, J.; Hu, D. Regulation of SIRT1 and Its Roles in Inflammation. Front. Immunol. 2022, 13, 831168. [Google Scholar] [CrossRef] [PubMed]
  37. Li, S.; He, Q.; Chen, B.; Zeng, J.; Dou, X.; Pan, Z.; Xiao, J.; Li, M.; Wang, F.; Chen, C.; et al. Cardamonin Protects against Iron Overload Induced Arthritis by Attenuating ROS Production and NLRP3 Inflammasome Activation via the SIRT1/p38MAPK Signaling Pathway. Sci. Rep. 2023, 13, 13744. [Google Scholar] [CrossRef] [PubMed]
  38. Chou, X.; Li, X.; Min, Z.; Ding, F.; Ma, K.; Shen, Y.; Sun, D.; Wu, Q. Sirtuin-1 Attenuates Cadmium-Induced Renal Cell Senescence through P53 Deacetylation. Ecotoxicol. Environ. Saf. 2022, 245, 114098. [Google Scholar] [CrossRef] [PubMed]
  39. Yu, Q.; Dong, L.; Li, Y.; Liu, G. SIRT1 and HIF1α Signaling in Metabolism and Immune Responses. Cancer Lett. 2018, 418, 20–26. [Google Scholar] [CrossRef] [PubMed]
  40. Bouras, T.; Fu, M.; Sauve, A.A.; Wang, F.; Quong, A.A.; Perkins, N.D.; Hay, R.T.; Gu, W.; Pestell, R.G. SIRT1 Deacetylation and Repression of P300 Involves Lysine Residues 1020/1024 within the Cell Cycle Regulatory Domain 1. J. Biol. Chem. 2005, 280, 10264–10276. [Google Scholar] [CrossRef] [PubMed]
  41. Wang, J.; Chen, J. SIRT1 Regulates Autoacetylation and Histone Acetyltransferase Activity of TIP60. J. Biol. Chem. 2010, 285, 11458–11464. [Google Scholar] [CrossRef] [PubMed]
  42. Zhang, J.; Xiang, H.; Liu, J.; Chen, Y.; He, R.-R.; Liu, B. Mitochondrial Sirtuin 3: New Emerging Biological Function and Therapeutic Target. Theranostics 2020, 10, 8315–8342. [Google Scholar] [CrossRef] [PubMed]
  43. Song, S.; Ding, Y.; Dai, G.; Zhang, Y.; Xu, M.; Shen, J.; Chen, T.; Chen, Y.; Meng, G. Sirtuin 3 Deficiency Exacerbates Diabetic Cardiomyopathy via Necroptosis Enhancement and NLRP3 Activation. Acta Pharmacol. Sin. 2021, 42, 230–241. [Google Scholar] [CrossRef] [PubMed]
  44. Fritz, K.S.; Galligan, J.J.; Smathers, R.L.; Roede, J.R.; Shearn, C.T.; Reigan, P.; Petersen, D.R. 4-Hydroxynonenal Inhibits SIRT3 via Thiol-Specific Modification. Chem. Res. Toxicol. 2011, 24, 651–662. [Google Scholar] [CrossRef] [PubMed]
  45. Giralt, A.; Hondares, E.; Villena, J.A.; Ribas, F.; Díaz-Delfín, J.; Giralt, M.; Iglesias, R.; Villarroya, F. Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α Controls Transcription of the Sirt3 Gene, an Essential Component of the Thermogenic Brown Adipocyte Phenotype. J. Biol. Chem. 2011, 286, 16958–16966. [Google Scholar] [CrossRef] [PubMed]
  46. Neeli, P.K.; Gollavilli, P.N.; Mallappa, S.; Hari, S.G.; Kotamraju, S. A Novel metadherinΔ7 Splice Variant Enhances Triple Negative Breast Cancer Aggressiveness by Modulating Mitochondrial Function via NFĸB-SIRT3 Axis. Oncogene 2020, 39, 2088–2102. [Google Scholar] [CrossRef] [PubMed]
  47. Nogueiras, R.; Habegger, K.M.; Chaudhary, N.; Finan, B.; Banks, A.S.; Dietrich, M.O.; Horvath, T.L.; Sinclair, D.A.; Pfluger, P.T.; Tschöp, M.H. Sirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism. Physiol. Rev. 2012, 92, 1479–1514. [Google Scholar] [CrossRef] [PubMed]
  48. Ahmed, M.A.; O’Callaghan, C.; Chang, E.D.; Jiang, H.; Vassilopoulos, A. Context-Dependent Roles for SIRT2 and SIRT3 in Tumor Development Upon Calorie Restriction or High Fat Diet. Front. Oncol. 2020, 9, 1462. [Google Scholar] [CrossRef] [PubMed]
  49. Han, C.; Someya, S. Maintaining Good Hearing: Calorie Restriction, Sirt3, and Glutathione. Exp. Gerontol. 2013, 48, 1091–1095. [Google Scholar] [CrossRef] [PubMed]
  50. Hebert, A.S.; Dittenhafer-Reed, K.E.; Yu, W.; Bailey, D.J.; Selen, E.S.; Boersma, M.D.; Carson, J.J.; Tonelli, M.; Balloon, A.J.; Higbee, A.J.; et al. Calorie Restriction and SIRT3 Trigger Global Reprogramming of the Mitochondrial Protein Acetylome. Mol. Cell 2013, 49, 186–199. [Google Scholar] [CrossRef] [PubMed]
  51. Fang, D.; Wang, Y.; Zhang, Z.; Yang, D.; Gu, D.; He, B.; Zhang, X.; He, D.; Wang, H.; Jose, P.A.; et al. Calorie Restriction Protects against Contrast-Induced Nephropathy via SIRT1/GPX4 Activation. Oxidative Med. Cell. Longev. 2021, 2021, 2999296. [Google Scholar] [CrossRef] [PubMed]
  52. Pardo, R.; Velilla, M.; Herrero, L.; Cervela, L.; Ribeiro, M.L.; Simó, R.; Villena, J.A. Calorie Restriction and SIRT1 Overexpression Induce Different Gene Expression Profiles in White Adipose Tissue in Association with Metabolic Improvement. Mol. Nutr. Food Res. 2021, 65, 2000672. [Google Scholar] [CrossRef] [PubMed]
  53. Kampmann, U.; Knorr, S.; Fuglsang, J.; Ovesen, P. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. J. Diabetes Res. 2019, 2019, 1–9. [Google Scholar] [CrossRef] [PubMed]
  54. Del Vecchio, G.; Li, Q.; Li, W.; Thamotharan, S.; Tosevska, A.; Morselli, M.; Sung, K.; Janzen, C.; Zhou, X.; Pellegrini, M.; et al. Cell-Free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes. Epigenetics 2021, 16, 642–661. [Google Scholar] [CrossRef] [PubMed]
  55. Lee, K.; Kuang, A.; Bain, J.R.; Hayes, M.G.; Muehlbauer, M.J.; Ilkayeva, O.R.; Newgard, C.B.; Powe, C.E.; Hivert, M.-F.; Scholtens, D.M.; et al. Metabolomic and Genetic Architecture of Gestational Diabetes Subtypes. Diabetologia 2024, 67, 895–907. [Google Scholar] [CrossRef] [PubMed]
  56. Khambule, L.; George, J.A. The Role of Inflammation in the Development of GDM and the Use of Markers of Inflammation in GDM Screening. In Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders; Guest, P.C., Ed.; Advances in Experimental Medicine and Biology; Springer International Publishing: Cham, Switzerland, 2019; Volume 1134, pp. 217–242. ISBN 978-3-030-12667-4. [Google Scholar]
  57. Chen, J.; Wang, Q.; Li, R.; Li, Z.; Jiang, Q.; Yan, F.; Ye, J. The role of sirtuins in the regulatin of oxidative stress during the progress and therapy of type 2 diabetes mellitus. Life Sci. 2023, 333, 122187. [Google Scholar] [CrossRef] [PubMed]
  58. Betsinger, C.N.; Cristea, I.M. Mitochondrial Function, Metabolic Regulation, and Human Disease Viewed through the Prism of Sirtuin 4 (SIRT4) Functions. J. Proteome Res. 2019, 18, 1929–1938. [Google Scholar] [CrossRef] [PubMed]
  59. Laurent, G.; German, N.J.; Saha, A.K.; de Boer, V.C.; Davies, M.; Koves, T.R.; Dephoure, N.; Fischer, F.; Boanca, G.; Vaitheesvaran, B.; et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol. Cell 2013, 50, 686–698. [Google Scholar] [CrossRef] [PubMed]
  60. Chang, S.; Zhang, G.; Li, L.; Li, H.; Jin, X.; Wang, Y.; Li, B. Sirt4 deficiency promotes the development of atherosclerosis by activating the NF-κB/IκB/CXCL2/3 pathway. Atherosclerosis 2023, 373, 29–37. [Google Scholar] [CrossRef] [PubMed]
  61. Gui, J.; Potthast, A.; Rohrbach, A.; Borns, K.; Das, A.M.; von Versen-Höynck, F. Gestational diabetes induces alterations of sirtuins in fetal endothelial cells. Pediatr. Res. 2016, 79, 788–798. [Google Scholar] [CrossRef] [PubMed]
  62. Zaganjor, E.; Vyas, S.; Haigis, M.C. SIRT4 Is a Regulator of Insulin Secretion. Cell Chem. Biol. 2017, 24, 656–658. [Google Scholar] [CrossRef] [PubMed]
  63. Maghbooli, Z.; Emamgholipour, S.; Aliakbar, S.; Amini, M.; Gorgani-Firuzjaee, S.; Hossein-Nezhad, A. Differential expressions of SIRT1, SIRT3, and SIRT4 in peripheral blood mononuclear cells from patients with type 2 diabetic retinopathy. Arch. Physiol. Biochem. 2020, 126, 363–368. [Google Scholar] [CrossRef] [PubMed]
Genes 16 00844 g001
Figure 1. The expression of SIRT1 in placenta of women with GDM and those with normal glucose tolerance. Each dot on the scatterplot represents one individual from the data set. * p < 0.05.
Figure 1. The expression of SIRT1 in placenta of women with GDM and those with normal glucose tolerance. Each dot on the scatterplot represents one individual from the data set. * p < 0.05.
Genes 16 00844 g001
Genes 16 00844 g002
Figure 2. The expression of SIRT3 in placenta of women with GDM and those with normal glucose tolerance. Each dot on the scatterplot represents one individual from the data set. * p < 0.05.
Figure 2. The expression of SIRT3 in placenta of women with GDM and those with normal glucose tolerance. Each dot on the scatterplot represents one individual from the data set. * p < 0.05.
Genes 16 00844 g002
Genes 16 00844 g003
Figure 3. The expression of SIRT4 in placenta of women with GDM and those with normal glucose tolerance. Each dot on the scatterplot represents one individual from the data set.
Figure 3. The expression of SIRT4 in placenta of women with GDM and those with normal glucose tolerance. Each dot on the scatterplot represents one individual from the data set.
Genes 16 00844 g003
Table 1. Clinical parameters in women with GDM and healthy women.
Table 1. Clinical parameters in women with GDM and healthy women.
ParametersGDMHealthy Controls
Mean ± SD
Age (years)32.3 ± 4.330.2 ± 4.8
Body mass before pregnancy (kg)70.9 ± 16.369.4 ± 18.5
Body mass at birth (kg)83.2 ± 15.781.1 ± 14.7
Body mass increase during pregnancy (kg)12.3 ± 6.011.7 ± 7.6
BMI before pregnancy (kg/m2)25.9 ± 5.524.7 ± 5.2
BMI at birth (kg/m2)30.4 ± 5.429.1 ± 4.3
BMI increase during pregnancy (kg/m2)4.5 ± 2.24.4 ± 2.6
Daily insulin requirement (unit)13.7 ± 15.80 ± 0
Newborn body mass (g)3401.9 ± 594.33318.6 ± 378.0
APGAR (0–10)9.3 ± 0.89.5 ± 0.7
Table 2. Correlations between SIRT1 expression in the placenta and clinical parameters in the GDM group.
Table 2. Correlations between SIRT1 expression in the placenta and clinical parameters in the GDM group.
Clinical Parameters Rsp
Age [years]0.280.16
APGAR [0–10]0.030.87
BMI at birth [kg/m2]−0.050.81
BMI before pregnancy [kg/m2]−0.050.80
BMI increase during pregnancy [kg/m2]0.030.87
Body mass at birth [kg]−0.080.71
Body mass before pregnancy [kg]0.040.83
Body mass increase during pregnancy [kg]0.080.70
Daily insulin requirement [unit]0.190.33
Newborn body mass [g]−0.040.86
Rs—Spearman rank correlation coefficient.
Table 3. Correlations between SIRT3 expression in the placenta and clinical parameters in the GDM group.
Table 3. Correlations between SIRT3 expression in the placenta and clinical parameters in the GDM group.
Clinical Parameters Rsp
Age [years]0.330.09
APGAR [0–10]−0.210.30
BMI at birth [kg/m2]−0.080.70
BMI before pregnancy [kg/m2]−0.120.56
BMI increase during pregnancy [kg/m2]0.080.71
Body mass at birth [kg]−0.110.58
Body mass before pregnancy [kg]−0.050.82
Body mass increase during pregnancy [kg]0.110.57
Daily insulin requirement [unit]0.150.46
Newborn body mass [g]−0.080.69
Rs—Spearman rank correlation coefficient.
Table 4. Correlations between SIRT4 expression in the placenta and clinical parameters in the GDM group.
Table 4. Correlations between SIRT4 expression in the placenta and clinical parameters in the GDM group.
Clinical ParametersRsp
Age [years]0.110.58
APGAR [0–10]0.090.67
BMI at birth [kg/m2]−0.200.31
BMI before pregnancy [kg/m2]−0.210.30
BMI increase during pregnancy [kg/m2]0.070.73
Body mass at birth [kg]−0.250.21
Body mass before pregnancy [kg]−0.170.41
Body mass increase during pregnancy [kg]0.090.66
Daily insulin requirement [unit]0.020.90
Newborn body mass [g]0.040.85
Rs—Spearman rank correlation coefficient.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Czerewaty, M.; Ustianowski, Ł.; Kiełbowski, K.; Bakinowska, E.; Safranow, K.; Tarnowski, M.; Sroczyński, T.; Pawlik, A. Placental Expression of Sirtuins in Women with Gestational Diabetes. Genes 2025, 16, 844. https://doi.org/10.3390/genes16070844

AMA Style

Czerewaty M, Ustianowski Ł, Kiełbowski K, Bakinowska E, Safranow K, Tarnowski M, Sroczyński T, Pawlik A. Placental Expression of Sirtuins in Women with Gestational Diabetes. Genes. 2025; 16(7):844. https://doi.org/10.3390/genes16070844

Chicago/Turabian Style

Czerewaty, Michał, Łukasz Ustianowski, Kajetan Kiełbowski, Estera Bakinowska, Krzysztof Safranow, Maciej Tarnowski, Tomasz Sroczyński, and Andrzej Pawlik. 2025. "Placental Expression of Sirtuins in Women with Gestational Diabetes" Genes 16, no. 7: 844. https://doi.org/10.3390/genes16070844

APA Style

Czerewaty, M., Ustianowski, Ł., Kiełbowski, K., Bakinowska, E., Safranow, K., Tarnowski, M., Sroczyński, T., & Pawlik, A. (2025). Placental Expression of Sirtuins in Women with Gestational Diabetes. Genes, 16(7), 844. https://doi.org/10.3390/genes16070844

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop